Lipocine Inc. Files 8-K

Ticker: LPCN · Form: 8-K · Filed: 2025-02-11T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: LPCN

TL;DR

Lipocine filed a routine 8-K, no major news yet.

AI Summary

Lipocine Inc. filed an 8-K on February 11, 2025, reporting other events and financial statements. The filing does not contain specific details about new events, material agreements, or financial results within the provided text, but indicates a standard regulatory filing.

Why It Matters

This filing indicates Lipocine Inc. is meeting its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without disclosing specific material events, suggesting no immediate new risks.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K filing?

The provided text for the 8-K filing indicates 'Other Events' as an item information, but does not specify the nature of these events.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted on February 11, 2025.

What is the principal executive office address for Lipocine Inc.?

The principal executive office address for Lipocine Inc. is 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

What is Lipocine Inc.'s Commission File Number?

Lipocine Inc.'s Commission File Number is 001-36357.

Does this filing include any new financial statements or exhibits?

Yes, the filing is categorized under 'Financial Statements and Exhibits', indicating that such documents are included, though their specific content is not detailed in the provided text.

From the Filing

0001493152-25-005809.txt : 20250211 0001493152-25-005809.hdr.sgml : 20250211 20250211090016 ACCESSION NUMBER: 0001493152-25-005809 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20250211 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250211 DATE AS OF CHANGE: 20250211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 25607849 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2025-02-11 2025-02-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): February 11, 2025     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit No.   Description       99.1   Corporate Presentation       104   Cover Page Interactive Data File (embedded within the Inline XBRL document)      

View on Read The Filing